Search for a doctor

Prashant Kapoor, M.D.

  1. Hematologist
  2. Oncologist
Request an Appointment

Publications

  1. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Bennett SA, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Kourelis T, Muchtar E, Zhou J, Rajkumar SV, Kumar SK, Olteanu H. FDA IDE validation of multiple myeloma MRD test by flow cytometry. Am J Hematol 2024 Dec; 99 (12):2399-2401 Epub 2024 Sept 18
    View PubMed
  2. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis TV, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Retreatment of Multiple Myeloma with Previously Refractory Drugs. Blood Adv. 2024 Nov 13 [Epub ahead of print]
    View PubMed
  3. Kapoor P. Checkpoint inhibition in macroglobulinaemia. Br J Haematol. 2024 Nov 5 Epub 2024 Nov 05
    View PubMed
  4. Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos MA, Huang SY, Spicka I, Chhabra S, Lichtman E, Mateos MV, Kanagavel D, Zhao L, Guillemin-Paveau H, Mace S, van de Velde H, Richardson PG. An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2024 Nov; 113 (5):593-605 Epub 2024 July 12
    View PubMed
  5. Chohan KL, Pruthi RK, Zanwar S, Paludo J, Go R, Pardanani A, Ashrani A, Cook JM, Thompson CA, Chanan-Khan A, Ailawadhi S, Habermann TM, Witzig TE, Gertz MA, Dingli D, Buadi FK, Dispenzieri A, Leung N, Kumar SK, Rajkumar V, Nichols WL, Kyle RA, Ansell SM, Kapoor P, Sridharan M, Abeykoon JP. The clinical impact of acquired von Willebrand syndrome secondary to Waldenstrom macroglobulinemia: an underrecognized source of major bleeding events. Leukemia. 2024 Nov; 38 (11):2497-2500 Epub 2024 Aug 28
    View PubMed
  6. Charalampous C, Goel U, Kapoor P, Binder M, Buadi F, Dingli D, Dispenzieri A, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, Kumar SK. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies. Clin Lymphoma Myeloma Leuk. 2024 Oct; 24 (10):e329-e335 Epub 2024 June 01
    View PubMed
  7. Chohan K, Paludo J, Dasari S, Mondello P, Novak J, Abeykoon JP, Wenzl K, Yang ZZ, Jalali S, Bhardwaj V, Krull JE, Braggio E, Manske MK, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan A, Kapoor P, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation. Blood. 2024 Sep 19; 144 (12):1284-1289
    View PubMed
  8. Zanwar S, Kapoor P. Diagnosis and Risk Stratification in Waldenstrom Macroglobulinemia. J Natl Compr Canc Netw. 2024 Sep; 22 (7)
    View PubMed
  9. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Kumar SK. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio >/=100. Leukemia. 2024 Aug; 38 (8):1862
    View PubMed
  10. Chohan KL, Kapoor P. Novel Approaches to Managing Patients with Relapsed and Refractory Waldenstrom Macroglobulinemia. Curr Hematol Malig Rep. 2024 Aug; 19 (4):163-174 Epub 2024 July 06
    View PubMed
  11. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Zhou J, Dispenzieri A, Kourelis T, Muchtar E, Rajkumar SV, Kumar SK, Olteanu H. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms. Blood Cancer J 2024 Jul 31; 14 (1):126 Epub 2024 July 31
    View PubMed
  12. Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, Ailawadhi S, Parrondo R, Chhabra S, Khot A, Hayman S, Dispenzieri A, Buadi F, Dingli D, Warsame R, Kapoor P, Gertz MA, Muchtar E, Kourelis T, Gonsalves W, Rajkumar SV, Lin Y, Kumar S. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024 Jul 23; 14 (1):122 Epub 2024 July 23
    View PubMed
  13. Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, Kumar S, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P. Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2024 Jul 20; 42 (21):2527-2536 Epub 2024 May 24
    View PubMed
  14. Tawfiq RK, Abeykoon JP, Kapoor P. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenstrom Macroglobulinemia. Curr Hematol Malig Rep. 2024 Jun; 19 (3):120-137 Epub 2024 Mar 27
    View PubMed
  15. Zanwar S, Gertz MA, Muchtar E, Buadi FK, Kourelis T, Gonsalves W, Go RS, Hayman S, Kapoor P, Binder M, Cook J, Dingli D, Leung N, Lin Y, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S, Dispenzieri A. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024 Jun; 38 (6):1423-1426 Epub 2024 Apr 09
    View PubMed
  16. Chohan K, Paludo J, Dasari S, Mondello P, Novak JP, Abeykoon JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Manske MK, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan A, Kapoor P, Kyle RA, Gertz MA, Novak AJ, Ansell SM. MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis. Haematologica 2024 May 1; 109 (5):1570-1575 Epub 2024 May 01
    View PubMed
  17. Christopoulos G, Attia ZI, Achenbach SJ, Rabe KG, Call TG, Ding W, Leis JF, Muchtar E, Kenderian SS, Wang Y, Hampel PJ, Koehler AB, Kay NE, Kapoor P, Slager SL, Shanafelt TD, Noseworthy PA, Friedman PA, Herrmann J, Parikh SA. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia. JACC CardioOncol. 2024 Apr; 6 (2):251-263 Epub 2024 Apr 16
    View PubMed
  18. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide. Blood Cancer J. 2024 Mar 26; 14 (1):55
    View PubMed
  19. Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Kumar SK. Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Mar; 24 (3):e104-e111.e1 Epub 2023 Nov 27
    View PubMed
  20. Abdallah NH, Lakshman A, Kumar SK, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Lin Y, Kourelis T, Warsame R, Bergsagel L, Rajkumar SV. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024 Jan 17; 14 (1):9
    View PubMed
  21. Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anticancer Drugs. 2024 Jan 1; 35 (1):63-69 Epub 2023 Apr 06
    View PubMed
  22. Abdallah NH, Nagayama H, Takahashi N, Gonsalves W, Fonder A, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hobbs M, Gertz MA, Binder M, Kapoor P, Warsame R, Hayman SR, Kourelis T, Hwa YL, Lin Y, Kyle RA, Rajkumar SV, Broski SM, Kumar SK. Muscle and fat composition in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2023 Dec 12; 13 (1):185
    View PubMed
  23. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma. Blood Cancer J 2023 Dec 11; 13 (1):183
    View PubMed
  24. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
    View PubMed
  25. Kapoor P, Rajkumar SV. Current approach to Waldenstrom macroglobulinemia. Blood Rev. 2023 Nov; 62:101129 Epub 2023 Aug 26
    View PubMed
  26. Luebker S, Frech TM, Assassi S, Skaug B, Gordon JK, Lakin K, Bernstein EJ, Luo Y, Steen VD, Shah AA, Hummers LK, Richardson C, Moore DF, Khanna D, Castelino FV, Chung L, Kapoor P, Hant FN, Shanmugam VK, VanBuren JM, Alvey J, Harding M, Shah A, Makol A, Lebiedz-Odrobina D, Thomas JK, Volkmann ER, Molitor JA, Sandorfi N. CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization. Rheumatology (Oxford). 2023 Oct 3; 62 (10):3433-3438
    View PubMed
  27. Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, Kumar S. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023 Oct; 98 (10):1540-1549 Epub 2023 July 08
    View PubMed
  28. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Go RS, Lin Y, Gonsalves WI, Binder M, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, Kumar SK. The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up. Amyloid. 2023 Sep; 30 (3):261-267 Epub 2022 Dec 19
    View PubMed
  29. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023 Aug 22; 7 (16):4371-4380
    View PubMed
  30. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023 Aug 22; 7 (16):4371-4380
    View PubMed
  31. Schmidt WM, Perera ND, Buadi FK, Hayman SR, Kumar SK, Dispenzieri A, Dingli D, Cook J, Lacy MQ, Kapoor P, Leung N, Muchtar E, Warsame RM, Kourelis T, Binder M, Gonsalves WI, Hogan WJ, Gertz MA. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma. Blood Cancer J. 2023 Aug 18; 13 (1):126
    View PubMed
  32. Talaulikar D, Tomowiak C, Toussaint E, Morel P, Kapoor P, Castillo JJ, Delmer A, Durot E. Evaluation and Management of Disease Transformation in Waldenstrom Macroglobulinemia. Hematol Oncol Clin North Am. 2023 Aug; 37 (4):787-799 Epub 2023 May 26
    View PubMed
  33. Visram A, Hayman SR, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Warsame R, Kourelis T, Cook J, Binder M, Gonsalves W, Muchtar E, Leung N, Roy V, Rajkumar SV, Kumar S. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Am J Hematol. 2023 Aug; 98 (8):1277-1285 Epub 2023 June 19
    View PubMed
  34. Kapoor P, Paludo J, Abeykoon JP. Frontline Management of Waldenstrom Macroglobulinemia with Chemoimmunotherapy. Hematol Oncol Clin North Am. 2023 Aug; 37 (4):671-687 Epub 2023 May 26
    View PubMed
  35. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Mauermann M, Witzig TE, Johnston P, Kyle RA, King RL, Habermann TM, Kumar S, Kapoor P. Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenstrom macroglobulinemia. Leuk Lymphoma 2023 Jul-Aug; 64 (8):1490-1493 Epub 2023 June 10
    View PubMed
  36. Chohan KL, Kapoor P. Btk inhibitors and other targeted therapies in Waldenstrom macroglobulinemia. Hemato. 2023 Jun; 4 (2):135-57
  37. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07
    View PubMed
  38. Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer J. 2023 May 15; 13 (1):78
    View PubMed
  39. Panakkal V, Lakshman A, Shi M, Olteanu H, Horna P, Timm MM, Otteson GE, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Rajkumar SV, Kumar SK, Jevremovic D. Utility of flow cytometry screening before MRD testing in multiple myeloma. Blood Cancer J 2023 Apr 20; 13 (1):55
    View PubMed
  40. Bansal R, Baksh M, Larsen JT, Hathcock MA, Dingli D, Stewart AK, Kapoor P, Kourelis T, Hayman SR, Warsame RM, Fonseca R, Bergsagel PL, Ailawadhi S, Kumar SK, Lin Y. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 2023 Apr 5; 13 (1):47 Epub 2023 Apr 05
    View PubMed
  41. Goldman-Mazur S, Visram A, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Binder M, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar SK. Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Adv. 2023 Mar 28; 7 (6):909-917
    View PubMed
  42. Chohan KL, Paludo J, Vallumsetla N, Larson D, King RL, He R, Gonsalves W, Inwards D, Witzig TE, Swaika A, Jain T, Leung N, Ailawadhi S, Reeder CB, Lacy MQ, Rajkumar SV, Kumar S, Kyle RA, Gertz MA, Ansell SM, Kapoor P. Survival trends in young patients with Waldenstrom macroglobulinemia: Over five decades of experience. Am J Hematol. 2023 Mar; 98 (3):432-439 Epub 2023 Jan 01
    View PubMed
  43. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. Am J Hematol. 2023 Mar; 98 (3):413-420 Epub 2023 Jan 01
    View PubMed
  44. D'Sa S, Matous JV, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, Talaulikar D, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Trotman J, Varettoni M, Vos J, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Kastritis E. Report of consensus panel 2 from the 11th international workshop on Waldenstrom's macroglobulinemia on the management of relapsed or refractory WM patients. Semin Hematol. 2023 Mar; 60 (2):80-89 Epub 2023 Mar 27
    View PubMed
  45. Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naive patients. Semin Hematol. 2023 Mar; 60 (2):73-79 Epub 2023 Mar 29
    View PubMed
  46. Tam CS, Kapoor P, Castillo JJ, Buske C, Ansell SM, Branagan AR, Kimby E, Li Y, Palomba ML, Qiu L, Shadman M, Abeykoon JP, Sarosiek S, Vos J, Yi S, Stephens D, Roos-Weil D, Roccaro AM, Morel P, Munshi NC, Anderson KC, San-Miguel J, Garcia-Sanz R, Dimopoulos MA, Treon SP, Kersten MJ. Report of consensus panel 7 from the 11th international workshop on Waldenstrom macroglobulinemia on priorities for novel clinical trials. Semin Hematol. 2023 Mar; 60 (2):118-124 Epub 2023 Mar 24
    View PubMed
  47. Mondello P, Paludo J, Novak JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Dasari S, Manske MK, Abeykoon JA, Sarangi V, Kapoor P, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan AA, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies. Clin Cancer Res. 2023 Mar 1; 29 (5):957-970
    View PubMed
  48. Nandakumar B, Baffour F, Abdallah NH, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Go RS, Kyle RA, Gertz MA, Rajkumar SV, Klug J, Korfiatis P, Gonsalves WI. Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma. Cancer. 2023 Feb 1; 129 (3):385-392 Epub 2022 Nov 22
    View PubMed
  49. Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. Leukemia. 2023 Jan; 37(1):1-4. Epub 2022 Dec 08.
    View PubMed
  50. Charalampous C, Goel U, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Buadi F, Kapoor P, Kourelis T, Warsame R, Hogan WJ, Kumar S. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma. Bone Marrow Transplant. 2023 Jan; 58 (1):46-53 Epub 2022 Oct 06
    View PubMed
  51. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
  52. Goldman-Mazur S, Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Kumar SK. Second- and third-line treatment strategies in multiple myeloma: a referral-center experience. Blood Cancer J. 2022 Dec 6; 12 (12):164 Epub 2022 Dec 06
    View PubMed
  53. Chohan KL, Abeykoon JP, Ansell SM, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Lacy MQ, Kyle RA, Go RS, Paludo J. Insurance-based disparities impact survival outcomes in Waldenstrom macroglobulinemia within the United States. Leuk Lymphoma. 2022 Dec; 63 (12):2879-2888 Epub 2022 July 23
    View PubMed
  54. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
  55. Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. Transplant Cell Ther. 2022 Nov; 28 (11):760.e1-760.e5 Epub 2022 Aug 05
    View PubMed
  56. Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA. Deepening responses after upfront autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in the era of novel agent induction therapy. Transplantation and Cellular Therapy. 2022 Nov; 28 (11):Pages 760.e1-5
  57. Abeykoon JP, Vaxman J, Patel SV, Kumar S, Malave GC, Young KS, Ailawadhi S, Larsen JT, Dispenzieri A, Muchtar E, Gonsalves WI, Kourelis T, Leung N, Warsame R, Go RS, Bergsagel L, Lacy MQ, Rajkumar SV, Gertz MA, Kapoor P. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. Br J Haematol. 2022 Oct; 199(1):95-99. Epub 2022 Jun 13.
    View PubMed
  58. Gertz MA, Warsame R, Muchtar E, Buadi F, Dispenzieri A, Gonsalves W, Dingli D, Hayman S, Kapoor P, Kourelis T, Kumar SK, Lacy MQ, Hogan W. Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2022 Oct; 63 (10):2422-2427 Epub 2022 May 12
    View PubMed
  59. Muchtar E, Gertz MA, LaPlant BR, Buadi FK, Leung N, O'Brien P, Bergsagel PL, Fonder A, Hwa YL, Hobbs M, Helgeson DK, Bradt EE, Gonsalves W, Lacy MQ, Kapoor P, Siddiqui M, Larsen JT, Warsame R, Hayman SR, Go RS, Dingli D, Kourelis TV, Dispenzieri A, Rajkumar SV, Kumar SK. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. Blood Adv. 2022 Sep 27; 6 (18):5429-5435
    View PubMed
  60. Durot E, Kanagaratnam L, Zanwar S, Toussaint E, Kastritis E, D'Sa S, Alcoceba M, Tomowiak C, Hivert B, Protin C, Abeykoon JP, Vos JMI, Michallet AS, Rodier C, Dupuis J, Lepretre S, Merabet F, Roussel X, Zini JM, Regny C, Patel A, Morel P, Roos-Weil D, Treon SP, Dimopoulos MA, Garcia-Sanz R, Kapoor P, Castillo JJ, Delmer AJ. High frequency of central nervous system involvement in transformed Waldenstrom macroglobulinemia. Blood Adv. 2022 Jun 28; 6 (12):3655-3658
    View PubMed
  61. Cook J, Peng KW, Witzig TE, Broski SM, Villasboas JC, Paludo J, Patnaik M, Rajkumar V, Dispenzieri A, Leung N, Buadi F, Bennani N, Ansell SM, Zhang L, Packiriswamy N, Balakrishnan B, Brunton B, Giers M, Ginos B, Dueck AC, Geyer S, Gertz MA, Warsame R, Go RS, Hayman SR, Dingli D, Kumar S, Bergsagel L, Munoz JL, Gonsalves W, Kourelis T, Muchtar E, Kapoor P, Kyle RA, Lin Y, Siddiqui M, Fonder A, Hobbs M, Hwa L, Naik S, Russell SJ, Lacy MQ. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 2022 Jun 14; 6 (11):3268-3279
    View PubMed
  62. Abeykoon J, Kumar S, Castillo JJ, D'Sa S, Kastritis E, Durot E, Uppal E, Pierre M, Paludo J, Tawfiq RK, Sarosiek S, Ogunbiyi O, Cornillet-Lefebvre P, Kyle RA, Delmer A, Gertz M, Dimopoulos M, Treon S, Ansell S, Kapoor P. Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study Journal of Clinical Oncology. 2022; 40(16_suppl):7566.
  63. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Kumar SK. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio >/=100. Leukemia. 2022 Jun; 36 (6):1699
    View PubMed
  64. Cook J, Gonsalves WI, Gertz MA, Visram A, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Kapoor P, Kourelis TV, Hayman SR, Kyle RA, Muchtar E, Kumar SK, Hogan WJ, Jacob EK, Buadi FK. Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. Bone Marrow Transplant 2022 Jun; 57 (6):1007-1009 Epub 2022 Apr 02
    View PubMed
  65. Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi F, Hwa L, Leung N, Lin Y, Gonsalves WI, Kourelis TV, Warsame R, Fonder A, Hobbs M, Binder M, Kyle RA, Rajkumar SV, Kumar SK. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv. 2022 May 10; 6 (9):2763-2772
    View PubMed
  66. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia. 2022 May; 36 (5):1449
    View PubMed
  67. El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, Barr H, Murphy C, Sakrikar D, Barnidge D, Bustoros M, Leblebjian H, Cowan A, Davis MI, Amstutz J, Boehner CJ, Lightbody ED, Sklavenitis-Pistofidis R, Perkins MC, Harding S, Mo CC, Kapoor P, Mikhael J, Borrello IM, Fonseca R, Weiss ST, Karlson E, Trippa L, Rebbeck TR, Getz G, Marinac CR, Ghobrial IM. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022 May; 9 (5):e340-e349 Epub 2022 Mar 25
    View PubMed
  68. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia 2022 May; 36 (5):1426-1428 Epub 2022 Jan 29
    View PubMed
  69. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Kumar SK. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio >/=100. Leukemia 2022 May; 36 (5):1429-1431 Epub 2022 Feb 21
    View PubMed
  70. Karam D, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Buadi F, Kapoor P, Kourelis T, Warsame R, Hogan W, Kumar S. Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant. Bone Marrow Transplant. 2022 May; 57 (5):803-809 Epub 2022 Mar 16
    View PubMed
  71. Al Saleh AS, Ebraheem MS, Sidiqi MH, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer J. 2022 Apr 11; 12 (4):59
    View PubMed
  72. Abdallah NH, Habermann T, Buadi FK, Gertz MA, Lacy MQ, Rajkumar SV, Dingli D, Go RS, Hayman SR, Kumar SK, Kourelis T, Warsame R, Kapoor P, Muchtar E, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Binder M, Siddiqui MA, Kyle RA, Witzig TE, Dispenzieri A. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol. 2022 Apr; 97(4):401-410. Epub 2022 Jan 19.
    View PubMed
  73. Heybeli C, Bentall AJ, Alexander MP, Amer H, Buadi FK, Dispenzieri A, Dingli D, Gertz MA, Issa N, Kapoor P, Kukla A, Kumar S, Lorenz EC, Rajkumar SV, Schinstock CA, Leung N. Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney Int Rep. 2022 Apr; 7 (4):752-762 Epub 2022 Jan 10
    View PubMed
  74. Visram A, Vachon C, Baughn LB, Larson D, Smadbeck J, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, Kumar S. Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. Leukemia. 2022 Apr; 36 (4):1058-1065 Epub 2021 Nov 11
    View PubMed
  75. Kaddoura M, Binder M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, Kumar S. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. Am J Hematol. 2022 Mar 01; 97(3):267-273. Epub 2022 Jan 03.
    View PubMed
  76. Zanwar S, Ho M, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Fonder A, Hobbs M, Hwa Y, Gonsalves W, Warsame R, Muchtar E, Leung N, Kyle RA, Rajkumar SV, Kumar S. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia 2022 Mar; 36 (3):873-876 Epub 2021 Oct 11
    View PubMed
  77. Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Gonsalves WI, Russell S, Lin Y, Siddiqui M, Kyle RA, Dispenzieri A, Kumar SK. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022 Mar; 36(3):801-808. Epub 2021 Oct 26.
    View PubMed
  78. Kapoor P, Gonsalves WI. Melflufen for multiple myeloma: a promise unfulfilled? Lancet Haematol 2022 Feb; 9 (2):e82-e84 Epub 2022 Jan 12
    View PubMed
  79. Mellors PW, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Dispenzieri A. Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. Am J Hematol. 2022 Feb 1; 97 (2):209-215 Epub 2021 Nov 30
    View PubMed
  80. Heybeli C, Alexander MP, Bentall AJ, Amer H, Buadi FK, Dean PG, Dingli D, Dispenzieri A, El Ters M, Gertz MA, Issa NS, Kapoor P, Kourelis T, Kukla A, Kumar S, Lacy MQ, Lorenz EC, Muchtar E, Murray DL, Nasr SH, Prieto M, Rajkumar SV, Schinstock CA, Stegall MD, Warsame R, Leung N. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series. Am J Kidney Dis. 2022 Feb; 79 (2):202-216 Epub 2021 June 24
    View PubMed
  81. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022 Jan 31; 12 (1):21
    View PubMed
  82. Muchtar E, Drake MT, Leung N, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Go RS, Binder M, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. Front Endocrinol (Lausanne). 2022; 13:891712 Epub 2022 June 21
    View PubMed
  83. Audil HY, Cook JM, Greipp PT, Kapoor P, Baughn LB, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Muchtar E, Siddiqui M, Gonsalves WI, Hwa YL, Leung N, Lin Y, Kourelis TV, Warsame R, Kyle RA, Ketterling RP, Rajkumar SV, Kumar SK. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am J Hematol. 2022 Jan 1; 97 (1):52-59 Epub 2021 Nov 03
    View PubMed
  84. Ravi G, Kapoor P. Current approach to Waldenstrom Macroglobulinemia. Cancer Treat Res Commun. 2022; 31:100527 Epub 2022 Feb 02
    View PubMed
  85. Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Reeder C, Sher T, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Go R, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Kristen M, Kapoor P, Gertz MA. "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. Blood Cancer J. 2021 Dec 7; 11 (12):196 Epub 2021 Dec 07
    View PubMed
  86. Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, Dean PG, Dispenzieri A, Dingli D, El Ters M, Gertz MA, Amer H, Kapoor P, Khamash H, Kourelis T, Kumar S, Lorenz EC, Mai M, Muchtar E, Murray DL, Prieto M, Schinstock CA, Stegall MD, Warsame R, Leung N. Corrigendum to Heybeli C, Bentall A, Wen J, et al. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney Int. 2021;99:707-715. Kidney Int. 2021 Dec; 100 (6):1348-1349
    View PubMed
  87. Al Saleh AS, Visram A, Parmar H, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Go RS, Gonsalves WI, Kourelis TV, Hayman SR, Kapoor P, Gertz MA, Kyle RA, Rajkumar SV, Kumar SK. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. Leuk Lymphoma. 2021 Dec; 62 (12):3011-3018 Epub 2021 July 15
    View PubMed
  88. Vaxman I, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Kapoor P, Grogan M, Go R, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Gertz MA, Dispenzieri A. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. Leukemia 2021 Dec; 35 (12):3604-3607 Epub 2021 May 21
    View PubMed
  89. Visram A, Rajkumar SV, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Baughn LB, Kyle RA, Kumar S. Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. Blood Cancer J. 2021 Nov 26; 11 (11):186
    View PubMed
  90. Durot E, Kanagaratnam L, Zanwar S, Kastritis E, D'Sa S, Garcia-Sanz R, Tomowiak C, Hivert B, Toussaint E, Protin C, Abeykoon JP, Guerrero-Garcia T, Itchaki G, Vos JM, Michallet AS, Godet S, Dupuis J, Lepretre S, Bomsztyk J, Morel P, Leblond V, Treon SP, Dimopoulos MA, Kapoor P, Delmer A, Castillo JJ. A prognostic index predicting survival in transformed Waldenstrom macroglobulinemia. Haematologica. 2021 Nov 1; 106 (11):2940-2946 Epub 2021 Nov 01
    View PubMed
  91. Kapoor P, Kumar S. Daratumumab for post-ASCT maintenance treatment of myeloma. Lancet Oncol. 2021 Oct; 22 (10):1345-1347 Epub 2021 Sept 13
    View PubMed
  92. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Colby C, Larson D, Paludo J, He R, Warsame R, Greipp PT, King RL, Thompson CA, Witzig TE, Lacy MQ, Gonsalves W, Nowakowski GS, Dingli D, Go RS, Habermann TM, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Disease outcomes and biomarkers of progression in smouldering Waldenstrom macroglobulinaemia. Br J Haematol. 2021 Oct; 195 (2):210-216 Epub 2021 Aug 02
    View PubMed
  93. Ho M, Zanwar S, Kapoor P, Gertz M, Lacy M, Dispenzieri A, Hayman S, Dingli D, Baudi F, Muchtar E, Leung N, Kourelis T, Warsame R, Fonder A, Hwa L, Hobbs M, Kyle R, Rajkumar SV, Kumar S. The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). Blood Cancer J. 2021 Sep 22; 11 (9):158 Epub 2021 Sept 22
    View PubMed
  94. Sidiqi MH, Al Saleh AS, Kumar SK, Leung N, Jevremovic D, Muchtar E, Gonsalves WI, Kourelis TV, Warsame R, Buadi FK, Lacy MQ, Kyle RA, Go R, Hobbs M, Dispenzieri A, Dingli D, Hayman SR, Gertz MA, Rajkumar SV, Kapoor P. Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. Am J Hematol. 2021 Sep 1; 96 (9):1131-1136 Epub 2021 July 05
    View PubMed
  95. Vaxman I, Muchtar E, Jacob E, Kapoor P, Kumar S, Dispenzieri A, Buadi F, Dingli D, Gonsalves W, Kourelis T, Warsame R, Lacy M, Hogan W, Gertz MA. The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplant Cell Ther. 2021 Sep; 27 (9):770.e1-770.e7 Epub 2021 June 18
    View PubMed
  96. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, Kumar S, Kapoor P. Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22
    View PubMed
  97. Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Broski SM, Rajkumar V, Kumar S. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021 Jul 13; 5 (13):2753-2759
    View PubMed
  98. Muchtar E, Dispenzieri A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Leung N, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Fonder A, Hobbs M, Go RS, Rajkumar SV, Kyle RA, Hogan WJ, Gertz MA. Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. Transplant Cell Ther. 2021 Jul; 27 (7):589.e1-589.e6 Epub 2021 Apr 08
    View PubMed
  99. Evans LA, Go R, Warsame R, Nandakumar B, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Kourelis TV, Russell S, Lust JA, Lin Y, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, Kumar S, Gonsalves WI. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clin Lymphoma Myeloma Leuk. 2021 Jul; 21 (7):451-460.e2 Epub 2021 Feb 17
    View PubMed
  100. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021 Jun 7; 11 (6):110 Epub 2021 June 07
    View PubMed
  101. Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021 Jun; 96(6):1546-1577.
    View PubMed
  102. Visram A, Vaxman I, S Al Saleh A, Parmar H, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Warsame R, Kourelis T, Siddiqui M, Gonsalves W, Muchtar E, Lust JA, Leung N, Kyle RA, Murray D, Rajkumar SV, Kumar S. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia. 2021 May; 35 (5):1428-1437 Epub 2021 Feb 23
    View PubMed
  103. Parrondo RD, Moustafa MA, Reeder C, Sher T, Roy V, Muchtar E, Warsame R, Alegria V, Gonsalves W, Dingli D, Hayman S, Kapoor P, Chanan-Khan AA, Ailawadhi S. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):355-360 Epub 2021 Jan 12
    View PubMed
  104. Vaxman I, Visram A, Kumar S, Dispenzieri A, Buadi F, Dingli D, Lacy M, Muchtar E, Kapoor P, Hogan W, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Berger T, Gertz MA. Autologous stem cell transplantation for multiple myeloma patients aged >/= 75 treated with novel agents. Bone Marrow Transplant. 2021 May; 56 (5):1144-1150 Epub 2020 Dec 04
    View PubMed
  105. Parmar H, Al Saleh AS, Visram A, Warsame R, Kourelis T, Gonsalves W, Dingli D, Muchtar E, Hayman S, Kapoor P, Buadi F, Dispenzieri A, Lacy M, Gertz M, Kumar S. Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplant Cell Ther. 2021 Apr; 27 (4):309.e1-309.e5 Epub 2020 Dec 17
    View PubMed
  106. Drosou ME, Vaughan LE, Muchtar E, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kourelis T, Kumar S, Kyle RA, Lacy MQ, Lin Y, Lopez CL, Lust JA, Rajkumar SV, Russell SJ, Sidana S, Siddiqui MA, Sidiqi MH, Warsame R, Leung N. Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. Am J Hematol. 2021 Apr 01; 96(4):446-454. Epub 2021 Jan 28.
    View PubMed
  107. Abeykoon JP, Murray DL, Murray I, Jevremovic D, Otteson GE, Dispenzieri A, Arendt BK, Dasari S, Gertz M, Gonsalves WI, Kourelis TV, Muchtar E, Dingli D, Warsame R, Go RS, Lacy MQ, Leung N, Buadi F, Lin Y, Kyle RA, Rajkumar V, Kumar S, Kapoor P. Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. Br J Haematol. 2021 Apr; 193 (2):380-385 Epub 2020 Nov 20
    View PubMed
  108. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021 Mar 4; 11 (3):50 Epub 2021 Mar 04
    View PubMed
  109. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Lisa Hwa Y, Fonder A, Hobbs M, Russell S, Lust JA, Siddiqui M, Vincent Rajkumar S, Kyle RA, Dispenzieri A. Characterization and prognostic implication of delayed complete response in AL amyloidosis. Eur J Haematol. 2021 Mar; 106 (3):354-361 Epub 2020 Dec 04
    View PubMed
  110. Kumar SK, Baz RC, Orlowski RZ, Anderson LD Jr, Ma H, Shrewsbury A, Croghan KA, Bilgi M, Kansagra A, Kapoor P, Li ZH, Brayer J. Results from lummicar-2: a phase 1b/2 study of fully human b-cell maturation antigen-specific car t cells (ct053) in patients with relapsed and/or refractory multiple myeloma Clinical Advances in Hematology & Oncology. 2021 Mar; 19 (3):18-9
  111. Sy-Go JPT, Dingli D, Gertz MA, Kapoor P, Buadi FK, Dispenzieri A, Lacy MQ, Fidler ME, Leung N. Acute Acquired Fanconi Syndrome in Multiple Myeloma After Hematopoietic Stem Cell Transplantation. Kidney Int Rep. 2021 Mar; 6 (3):857-864 Epub 2020 Dec 19
    View PubMed
  112. Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Siddiqui M, Go RS, Jevremovic D, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clin Proc. 2021 Mar; 96 (3):677-687
    View PubMed
  113. Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, Gertz MA, Buadi F, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Dingli D, Fonder A, Hayman S, Hobbs M, Hwa YL, Kyle R, Leung N, Go R, Rajkumar VS, Kumar S. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. Am J Hematol. 2021 Mar 1; 96 (3):330-337 Epub 2021 Jan 13
    View PubMed
  114. Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, Dean PG, Dispenzieri A, Dingli D, El Ters M, Gertz MA, Hatem A, Kapoor P, Khamash H, Kourelis T, Kumar S, Lorenz EC, Mai M, Muchtar E, Murray DL, Prieto M, Schinstock CA, Stegall MD, Warsame R, Leung N. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney Int. 2021 Mar; 99 (3):707-715 Epub 2020 July 23
    View PubMed
  115. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Lust JA, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, Kumar SK. Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Adv. 2021 Feb 23; 5 (4):1029-1036
    View PubMed
  116. Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, Advani RH, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP. Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 Feb; 192 (3):542-550 Epub 2020 Nov 18
    View PubMed
  117. Gunaratne MDSK, Sahakian AJ, Abeykoon JP, Ansell SM, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Novak AJ, Lacy MQ, Kyle RA, Go RS, Paludo J. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2021 Feb; 62(2):308-315. Epub 2020 Oct 15.
    View PubMed
  118. Pang L, Rajkumar SV, Kapoor P, Buadi F, Dispenzieri A, Gertz M, Lacy M, Kyle R, Kumar S. Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer J. 2021 Feb 1; 11 (2):26 Epub 2021 Feb 01
    View PubMed
  119. Abdallah N, Muchtar E, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Pruthi RK, Gertz MA, Kumar SK. Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clin Proc. 2021 Feb; 96 (2):377-387
    View PubMed
  120. Vaxman I, Visram A, Pasvolsky O, Kumar S, Dispenzieri A, Buadi F, Dingli D, Lacy M, Hayman S, Kyle R, Kapoor P, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M. Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leuk Lymphoma. 2021 Feb; 62 (2):316-322 Epub 2020 Oct 29
    View PubMed
  121. Abeykoon JP, Wu X, Nowakowski KE, Dasari S, Paludo J, Weroha SJ, Hu C, Hou X, Sarkaria JN, Mladek AC, Phillips JL, Feldman AL, Ravindran A, King RL, Boysen J, Stenson MJ, Carr RM, Manske MK, Molina JR, Kapoor P, Parikh SA, Kumar S, Robinson SI, Yu J, Boughey JC, Wang L, Goetz MP, Couch FJ, Patnaik MM, Witzig TE. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood. 2021 Jan 28; 137 (4):513-523
    View PubMed
  122. Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, Liedtke M, Jaccard A, Wechalekar AD, Comenzo R, Sanchorawala V, Royer B, Rosenzweig M, Valent J, Schonland S, Fonseca R, Wong S, Kapoor P. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021 Jan 11; 11 (1):10
    View PubMed
  123. Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clin Cancer Res. 2020 Dec 15; 26 (24):6581-6588 Epub 2020 Oct 02
    View PubMed
  124. Visram A, Al Saleh AS, Parmar H, McDonald JS, Lieske JC, Vaxman I, Muchtar E, Hobbs M, Fonder A, Hwa YL, Buadi FK, Dingli D, Lacy MQ, Dispenzieri A, Kapoor P, Hayman SR, Warsame R, Kourelis TV, Siddiqui M, Gonsalves WI, Lust JA, Kyle RA, Vincent Rajkumar S, Gertz MA, Kumar SK, Leung N. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer J. 2020 Dec 11; 10 (12):124
    View PubMed
  125. Vaxman I, Al Saleh AS, Kumar S, Nitin M, Mishra N, Dispenzieri A, Buadi F, Dingli D, Lacy M, Muchtar E, Hobbs M, Fonder A, Hwa L, Visram A, Kapoor P, Siddiqui M, Lust J, Kyle R, Rajkumar V, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz MA. Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. Cancer Med. 2020 Dec; 9 (23):8895-8901 Epub 2020 Oct 06
    View PubMed
  126. Abeykoon J, Wu X, Nowakowski KE, Dasari S, Paludo J, Weroha SJ, Hu C, Hou X, Sarkaria JN, Mladek AC, Phillips JL, Feldman A, Ravindran A, King RL, Boysen JC, Stenson M, Carr RM, Manske MK, Molina JR, Kapoor P, Parikh SA, Kumar SK, Robinson SI, Yu J, Boughey JC, Wang L, Goetz MP, Couch FJ, Patnaik MM, Witzig TE. CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair. Blood. 2020 Nov 2 Epub 2020 Nov 02
    View PubMed
  127. Al Saleh AS, Sidiqi MH, Lee J, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Skaer CA, Wittwer SK, Wolf RC, Hogan WJ, Kumar SK, Jacob E, Gertz MA. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Bone Marrow Transplant. 2020 Nov; 55 (11):2132-2137 Epub 2020 May 01
    View PubMed
  128. Muchtar E, Gertz MA, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Fonder A, Hobbs M, Russell S, Lust JA, Siddiqui M, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A. Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. Am J Hematol. 2020 Nov; 95 (11):1280-1287 Epub 2020 Aug 24
    View PubMed
  129. Richardson PG, Lee HC, Abdallah AO, Cohen AD, Kapoor P, Voorhees PM, Hoos A, Wang K, Baron J, Piontek T, Byrne J, Richmond S, Jewell RC, Opalinska J, Gupta I, Lonial S. Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020 Oct 23; 10 (10):106
    View PubMed
  130. Tschautscher MA, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell SJ, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Vincent Rajkumar S, Kumar S. Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer J 2020 Oct 2; 10 (10):95 Epub 2020 Oct 02
    View PubMed
  131. Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 Oct; 21 (10):1317-1330 Epub 2020 Aug 28
    View PubMed
  132. Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A. Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. 2020 Oct; 34 (10):2819
    View PubMed
  133. Al Saleh AS, Parmar HV, Visram A, Muchtar E, Buadi FK, Go RS, Dispenzieri A, Kapoor P, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Kyle RA, Rajkumar SV, Kumar SK. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2020 Sep; 20 (9):596-601 Epub 2020 Apr 07
    View PubMed
  134. Paquin A, Visram A, Kumar SK, Gertz MA, Cantwell H, Buadi FK, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. Blood Cancer J. 2020 Aug 28; 10 (8):87
    View PubMed
  135. Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV, Kumar SK. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020 Aug 11; 4 (15):3509-3519
    View PubMed
  136. Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020 Aug 11; 10 (8):82
    View PubMed
  137. Al Saleh AS, Sidiqi MH, Muchtar E, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 Aug; 26 (8):1402-1405 Epub 2020 May 15
    View PubMed
  138. Abdallah N, Sidana S, Dispenzieri A, Lacy M, Buadi F, Hayman S, Kapoor P, Leung N, Dingli D, Hwa YL, Lust J, Russell S, Gonsalves W, Go R, Hogan W, Kyle R, Rajkumar SV, Gertz M, Kumar S. Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplant. 2020 Jul; 55 (7):1297-1304 Epub 2020 June 09
    View PubMed
  139. Evans LA, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Go R, Russell S, Lust JA, Lin Y, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, Kumar SK, Gonsalves WI. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. Am J Hematol. 2020 Jun; 95 (6):637-642 Epub 2020 Mar 26
    View PubMed
  140. Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, Jevremovic D, Pearce KE, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020 May 26; 4 (10):2236-2244
    View PubMed
  141. Bonolo de Campos C, Meurice N, Petit JL, Polito AN, Zhu YX, Wang P, Bruins LA, Wang X, Lopez Armenta ID, Darvish SA, Ahmann GJ, Henderson KJ, Tian S, Kruse JJ, Stewart WM, Larsen JT, Reeder CB, Dingli D, Kapoor P, Kumar SK, Fonseca R, Bergsagel PL, Braggio E, Stewart AK. "Direct to Drug" screening as a precision medicine tool in multiple myeloma. Blood Cancer J. 2020 May 11; 10 (5):54
    View PubMed
  142. Sidiqi MH, Al Saleh AS, Leung N, Jevremovic D, Aljama MA, Gonsalves WI, Buadi FK, Kourelis TV, Warsame R, Muchtar E, Hobbs MA, Lacy MQ, Dingli D, Go RS, Hayman SR, Rajkumar SV, Dispenzieri A, Gertz MA, Kumar SK, Fonseca R, Kapoor P. Venetoclax for the treatment of translocation (11;14) AL amyloidosis. Blood Cancer J 2020 May 11; 10 (5):55
    View PubMed
  143. Sidiqi MH, Aljama M, Kumar SK, Jevremovic D, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Fonder AL, Hobbs MA, Hwa YL, Kapoor P, Kourelis T, Leung N, Muchtar E, Lust JA, Kyle RA, Go RS, Rajkumar VS, Gertz MA, Dispenzieri A. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied? Blood Cancer J. 2020 May 6; 10 (5):52 Epub 2020 May 06
    View PubMed
  144. Sidana S, Muchtar E, Sidiqi MH, Jevremovic D, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Gertz MA, Kumar SK. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. Am J Hematol. 2020 May; 95 (5):497-502 Epub 2020 Feb 14
    View PubMed
  145. Sidana S, Larson DP, Greipp PT, He R, McPhail ED, Dispenzieri A, Murray DL, Dasari S, Ansell SM, Muchtar E, Gonsalves WI, Kourelis TV, Ramirez-Alvarado M, Kapoor P, Rajkumar SV, Lacy MQ, Buadi FK, Leung N, Kyle RA, Kumar SK, King RL, Gertz MA. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020 May; 34 (5):1373-1382 Epub 2019 Nov 28
    View PubMed
  146. Sidana S, Milani P, Binder M, Basset M, Tandon N, Foli A, Dispenzieri A, Gertz MA, Hayman SR, Buadi FK, Lacy MQ, Kapoor P, Leung N, Rajkumar SV, Merlini G, Palladini G, Kumar SK. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J. 2020 Apr 14; 10 (4):41
    View PubMed
  147. Seth S, Zanwar S, Vu L, Kapoor P. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. Curr Hematol Malig Rep. 2020 Apr; 15 (2):45-55
    View PubMed
  148. Muchtar E, Gertz MA, Kourelis TV, Sidana S, Go RS, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Lisa Hwa Y, Gonsalves W, Warsame R, Russell S, Lust JA, Lin Y, Zeldenrust S, Rajkumar SV, Kyle RA, Kumar SK, Dispenzieri A. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia. 2020 Apr; 34 (4):1135-1143 Epub 2019 Nov 22
    View PubMed
  149. Tschautscher M, Jevremovic D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Russell S, Leung N, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, Kumar S. Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity. Am J Hematol 2020 Mar; 95 (3):E60-E62 Epub 2019 Dec 30
    View PubMed
  150. Gonsalves WI, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui MA, Kyle RA, Gertz MA, Rajkumar SV, Kumar SK. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. Am J Hematol. 2020 Mar; 95 (3):310-315 Epub 2020 Jan 08
    View PubMed
  151. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2020 Mar; 95(3):274-281. Epub 2019 Dec 31.
    View PubMed
  152. Muchtar E, Dispenzieri A, Jevremovic D, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Warsame R, Kourelis TV, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid. 2020 Mar; 27 (1):13-16 Epub 2019 Sept 23
    View PubMed
  153. Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar SK, Leung N, Muchtar E, Buadi FK, Warsame R, Kyle RA, Lacy MQ, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hayman SR, Hwa YL, Fonder A, Hobbs M, Jevremovic D, Lust JA, Zeldenrust S, Russell SJ, Rajkumar SV, Gertz MA, Murray D. Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. Blood Cancer J. 2020 Feb 25; 10 (2):20
    View PubMed
  154. Zanwar S, Abeykoon JP, Kapoor P. Novel Treatment Strategies in the Management of Waldenstrom Macroglobulinemia. Curr Hematol Malig Rep. 2020 Feb; 15 (1):31-43
    View PubMed
  155. Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020 Feb; 188 (3):394-403 Epub 2019 Aug 29
    View PubMed
  156. Abdallah N, Kapoor P, Murray DL, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Kourelis TV, Lacy MQ, Leung N, Lust JA, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Adv. 2020 Jan 28; 4 (2):322-326
    View PubMed
  157. Warsame R, LaPlant B, Kumar SK, Laumann K, Perez Burbano G, Buadi FK, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves WI, Kourelis T, Lust J, Russell SJ, Zeldenrust S, Lin Y, Muchtar E, Go RS, Vincent Rajkumar S, Dispenzieri A. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer J. 2020 Jan 8; 10 (1):4 Epub 2020 Jan 08
    View PubMed
  158. Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Siddiqui M, Zeldenrust S, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. Clin Lymphoma Myeloma Leuk. 2020 Jan; 20 (1):53-56 Epub 2019 Oct 09
    View PubMed
  159. Al Saleh AS, Sidiqi MH, Dispenzieri A, Kapoor P, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kourelis TV, Gertz MA, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. Am J Hematol. 2020 Jan; 95 (1):4-9 Epub 2019 Oct 29
    View PubMed
  160. Miller KC, Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Muchtar E, Hogan WJ, Kumar SK. The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2019 Dec; 54 (12):2039-2050 Epub 2019 June 12
    View PubMed
  161. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leuk Lymphoma. 2019 Dec; 60 (12):2960-2967 Epub 2019 May 16
    View PubMed
  162. Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. Br J Haematol. 2019 Dec; 187 (5):588-594 Epub 2019 July 12
    View PubMed
  163. Sidiqi MH, Nadiminti K, Al Saleh AS, Meleveedu K, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA. Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function. Bone Marrow Transplant. 2019 Nov; 54 (11):1775-1779 Epub 2019 Apr 08
    View PubMed
  164. Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, Buadi FK, Leung N, Gonsalves WI, Kourelis TV, Warsame RM, Dispenzieri A, Lacy MQ, Kyle RA, Rajkumar SV, Paludo J. Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer. 2019 Oct 15; 125 (20):3574-3581 Epub 2019 June 28
    View PubMed
  165. Al Saleh AS, Sidiqi MH, Sidana S, Muchtar E, Dispenzieri A, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Wolf RC, Kapoor P, Buadi FK, Kumar SK, Gertz MA. Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. Am J Hematol. 2019 Oct; 94 (10):1066-1071 Epub 2019 July 23
    View PubMed
  166. Sidana S, Sidiqi MH, Dispenzieri A, Buadi FK, Lacy MQ, Muchtar E, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Leung N, Warsame R, Kourelis TV, Wolf RC, Hogan WJ, Kumar SK, Gertz MA. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. Am J Hematol. 2019 Sep; 94 (9):1020-1026 Epub 2019 July 11
    View PubMed
  167. Al Saleh AS, Sidiqi MH, Muchtar E, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Warsame RM, Gonsalves WI, Kourelis TV, Hogan WJ, Hayman SR, Kapoor P, Kumar SK, Gertz MA. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. Biol Blood Marrow Transplant. 2019 Aug; 25 (8):1520-1525 Epub 2019 May 02
    View PubMed
  168. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Impact of acquired del(17p) in multiple myeloma. Blood Adv. 2019 Jul 09; 3(13):1930-1938.
    View PubMed
  169. Tschautscher MA, Jevremovic D, Rajkumar V, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. Am J Hematol. 2019 Jul; 94 (7):751-756 Epub 2019 Apr 30
    View PubMed
  170. Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. Bone Marrow Transplant. 2019 Jul; 54 (7):1077-1081 Epub 2018 Nov 02
    View PubMed
  171. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant. 2019 Jun; 25 (6):1099-1106 Epub 2019 Feb 20
    View PubMed
  172. Kapoor P, Rajkumar SV. MAIA under the microscope - bringing trial design into focus. Nat Rev Clin Oncol. 2019 Jun; 16 (6):339-340
    View PubMed
  173. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia. J Clin Oncol. 2019 Jun 1; 37 (16):1403-1411 Epub 2019 Apr 16
    View PubMed
  174. Sidiqi MH, Dasari S, McPhail ED, Buadi FK, Warsame R, Lacy MQ, Dingli D, Gonsalves WI, Kapoor P, Kourelis T, Leung N, Muchtar E, Grogan M, Lust JA, Kumar S, Kyle RA, Rajkumar VS, Gertz M, Dispenzieri A. Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. Am J Hematol 2019 May; 94 (5):E141-E143 Epub 2019 Feb 27
    View PubMed
  175. Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder AL, Hobbs MA, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis TV, Warsame R, Kyle RA, Kumar SK. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. 2019 May; 33 (5):1273-1277 Epub 2019 Feb 20
    View PubMed
  176. Sidana S, Tandon N, Gertz MA, Dispenzieri A, Ramirez-Alvarado M, Murray DL, Kourelis TV, Buadi FK, Kapoor P, Gonsalves W, Warsame R, Lacy MQ, Kyle RA, Rajkumar SV, Kumar SK, Leung N. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. Br J Haematol. 2019 May; 185 (4):701-707 Epub 2019 Mar 05
    View PubMed
  177. Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019 May; 33 (5):1268-1272 Epub 2019 Feb 08
    View PubMed
  178. Aljama MA, Sidiqi MH, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. Blood Adv. 2019 Apr 23; 3 (8):1226-1229
    View PubMed
  179. Zanwar S, Abeykoon JP, Kapoor P. Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. Curr Hematol Malig Rep. 2019 Apr; 14 (2):70-82
    View PubMed
  180. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Substratification of patients with newly diagnosed standard-risk multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):254-260 Epub 2019 Feb 15
    View PubMed
  181. Sidana S, Jevremovic D, Ketterling RP, Tandon N, Dispenzieri A, Gertz MA, Greipp PT, Baughn LB, Buadi FK, Lacy MQ, Morice W, Hanson C, Timm M, Dingli D, Hayman SR, Gonsalves WI, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Rajkumar SV, Kumar SK. Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. Am J Hematol. 2019 Apr; 94 (4):424-430 Epub 2019 Jan 08
    View PubMed
  182. Miller KC, Gertz MA, Buadi FK, Hayman SR, Wolf RC, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Hogan WJ, Kumar SK. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2019 Apr; 54 (4):587-594 Epub 2018 Aug 16
    View PubMed
  183. Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Dispenzieri A, Kourelis TV, Warsame R, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Hwa YL, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Kumar SK. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv. 2019 Mar 12; 3 (5):744-750
    View PubMed
  184. Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Dispenzieri A, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J. 2019 Mar 07; 9(3):32.
    View PubMed
  185. Sidana S, Tandon N, Brady PA, Grogan M, Gertz MA, Dispenzieri A, Lin G, Dingli D, Buadi FK, Lacy MQ, Kapoor P, Gonsalves WI, Muchtar E, Warsame R, Kumar SK, Kourelis TV. Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. Mayo Clin Proc. 2019 Mar; 94 (3):455-464 Epub 2019 Feb 02
    View PubMed
  186. Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, Buadi FK, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Kumar SK, Dispenzieri A. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. Mayo Clin Proc. 2019 Mar; 94 (3):472-483 Epub 2019 Feb 13
    View PubMed
  187. Muchtar E, Therneau TM, Larson DR, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Fonder A, Hobbs M, Hwa YL, Leung N, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Comparative analysis of staging systems in AL amyloidosis. Leukemia 2019 Mar; 33 (3):811-814 Epub 2019 Jan 23
    View PubMed
  188. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019 Mar; 33 (3):790-794 Epub 2018 Oct 12
    View PubMed
  189. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK. Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. Leukemia. 2019 Mar; 33 (3):730-738 Epub 2018 Oct 15
    View PubMed
  190. Sidiqi MH, Buadi FK, Dispenzieri A, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis. Biol Blood Marrow Transplant. 2019 Mar; 25 (3):e108-e111 Epub 2018 Dec 07
    View PubMed
  191. Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. Am J Hematol. 2019 Mar; 94 (3):306-311 Epub 2018 Dec 13
    View PubMed
  192. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09
    View PubMed
  193. Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Muchtar E, Lust JA, Rajkumar VS, Gertz MA. Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. Bone Marrow Transplant. 2019 Mar; 54 (3):442-447 Epub 2018 Aug 07
    View PubMed
  194. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia. 2019 Feb; 33 (2):527-531 Epub 2018 Sept 26
    View PubMed
  195. Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, Gonsalves W, Muchtar E, Dingli D, Lacy MQ, Hayman SR, Buadi F, Warsame R, Kyle RA, Rajkumar V, Kumar S, Kapoor P. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019 Feb; 33 (2):531-536 Epub 2018 Sept 28
    View PubMed
  196. Kapoor P, Rajkumar SV. Smoldering Multiple Myeloma: To Treat or Not to Treat. Cancer J. 2019 Jan/Feb; 25 (1):65-71
    View PubMed
  197. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid. 2019; 26(sup1):101-102.
    View PubMed
  198. Abad CL, Phuoc V, Kapoor P, Tosh PK, Sia IG, Osmon DR, Tande AJ. Bone and Joint Infections among Hematopoietic Stem Cell Transplant Recipients. J Bone Jt Infect. 2019; 4 (5):209-215 Epub 2019 Sept 18
    View PubMed
  199. Paquin AR, Kumar SK, Buadi FK, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer J. 2018 Dec 11; 8 (12):125
    View PubMed
  200. Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK. Utility and prognostic value of (18) F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018 Dec; 93 (12):1518-1523 Epub 2018 Oct 02
    View PubMed
  201. Aljama MA, Sidiqi MH, Lakshman A, Dispenzieri A, Jevremovic D, Gertz MA, Lacy MQ, Buadi FK, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame R, Kourelis TV, Hwa YL, Kapoor P, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018 Nov 27; 2(22):3149-3154.
    View PubMed
  202. Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018 Nov 15; 8 (12):116
    View PubMed
  203. Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. Blood Cancer J. 2018 Nov 8; 8 (11):106 Epub 2018 Nov 08
    View PubMed
  204. Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Nov; 93 (11):1384-1393 Epub 2018 Oct 02
    View PubMed
  205. Sidiqi MH, Aljama MA, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz MA. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. Biol Blood Marrow Transplant. 2018 Nov; 24 (11):2360-2364 Epub 2018 June 30
    View PubMed
  206. Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma. Expert Rev Hematol. 2018 Oct; 11 (10):761-771
    View PubMed
  207. Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA. Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. Biol Blood Marrow Transplant. 2018 Oct; 24 (10):2157-2159 Epub 2018 June 20
    View PubMed
  208. Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle R, Kumar S. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. Am J Hematol. 2018 Oct; 93 (10):1207-1210 Epub 2018 Aug 15
    View PubMed
  209. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018 Oct; 32 (10):2240-2249 Epub 2018 Feb 20
    View PubMed
  210. Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, Rajkumar SV, Kyle RA, Hogan W, Kumar SK. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2018 Oct; 24 (10):2127-2132 Epub 2018 Apr 12
    View PubMed
  211. Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018 Aug; 97 (8):1417-1425 Epub 2018 Apr 03
    View PubMed
  212. Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia. 2018 Aug; 32(8):1811-1815. Epub 2018 Jan 30.
    View PubMed
  213. Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018 Jul 30; 8 (8):70 Epub 2018 July 30
    View PubMed
  214. Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, Thompson CA, Fervenza FC, Zand L, Hwa YL, Jevremovic D, Shi M, Leung N. Kidney Involvement of Patients with Waldenstrom Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. Clin J Am Soc Nephrol. 2018 Jul 6; 13 (7):1037-1046 Epub 2018 May 30
    View PubMed
  215. Fang H, Kapoor P, Gonsalves WI, Frederick LA, Viswanatha D, Howard MT, He R, Morice WG 2nd, McPhail ED, Greipp PT, Ansell SM, Kyle RA, Gertz MA, Paludo J, Abeykoon J, King RL. Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation? Am J Clin Pathol. 2018 Jul 3; 150 (2):168-176
    View PubMed
  216. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. Am J Hematol. 2018 Jul; 93 (7):889-894
    View PubMed
  217. Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M. Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation. Haematologica. 2018 Jul; 103 (7):1229-1234 Epub 2018 Apr 19
    View PubMed
  218. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. Br J Haematol. 2018 Jul; 182 (1):71-77 Epub 2018 Apr 29
    View PubMed
  219. Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2018 Jul; 32 (7):1567-1574 Epub 2018 Feb 23
    View PubMed
  220. Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018 Jun 12; 8(6):59.
    View PubMed
  221. Kyle RA, Larson DR, McPhail ED, Therneau TM, Dispenzieri A, Kumar S, Kapoor P, Cerhan JR, Rajkumar SV. Fifty-Year Incidence of Waldenstrom Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clin Proc. 2018 Jun; 93 (6):739-746 Epub 2018 Apr 12
    View PubMed
  222. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia. 2018 Jun; 32 (6):1421-1426 Epub 2018 Feb 21
    View PubMed
  223. Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Dingli D, Rajkumar SV, Dispenzieri A, Grogan M. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid. 2018 Jun; 25 (2):86-92 Epub 2018 Mar 12
    View PubMed
  224. Goyal G, Bartley AC, Funni S, Inselman J, Shah ND, Marshall AL, Ashrani AA, Kapoor P, Durani U, Hashmi SK, Siddiqui MA, Buadi FK, Go RS, Kyle RA, Kumar S, Gonsalves WI. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia. 2018 Jun; 32 (6):1414-1420 Epub 2018 Mar 21
    View PubMed
  225. Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M. Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circ Cardiovasc Imaging. 2018 May; 11 (5):e006588
    View PubMed
  226. Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ, Gertz MA. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018 May 1; 36 (13):1323-1329 Epub 2018 Mar 20
    View PubMed
  227. Kapoor P, Gertz MA, Ansell SM. Fitting mSMART Into the Current Clinical Management of Waldenstrom Macroglobulinemia-Reply. JAMA Oncol 2018 May 1; 4 (5):745-746
    View PubMed
  228. Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kumar SK, Kapoor P, Kourelis TV, Hogan WJ, Gertz MA. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv. 2018 Apr 10; 2 (7):769-776
    View PubMed
  229. McCullough KB, Hobbs MA, Abeykoon JP, Kapoor P. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. Curr Hematol Malig Rep. 2018 Apr; 13 (2):114-124
    View PubMed
  230. Sidana S, Tandon N, Gertz MA, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Hogan WJ, Kumar SK. Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplant. 2018 Mar; 53 (3):326-333 Epub 2017 Dec 21
    View PubMed
  231. Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018 Mar; 32 (3):729-735 Epub 2017 Sept 18
    View PubMed
  232. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia. 2018 Mar; 32 (3):712-718 Epub 2017 Aug 14
    View PubMed
  233. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01
    View PubMed
  234. Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2018 Feb 23 [Epub ahead of print]
    View PubMed
  235. Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2018 Feb; 93(2):179-186. Epub 2017 Nov 10.
    View PubMed
  236. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Feb; 93 (2):187-194 Epub 2017 Nov 17
    View PubMed
  237. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. Bone Marrow Transplant. 2018 Feb; 53 (2):155-161 Epub 2017 Nov 13
    View PubMed
  238. Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Kumar SK. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). Am J Hematol. 2018 Jan; 93 (1):17-22 Epub 2017 Oct 20
    View PubMed
  239. Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ. Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma. Mayo Clin Proc. 2018 Jan; 93 (1):56-58
    View PubMed
  240. Lakshman A, Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Natural history of t(11;14) multiple myeloma. Leukemia. 2018 Jan; 32(1):131-138. Epub 2017 Jun 27.
    View PubMed
  241. Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia. 2017 Dec 18 [Epub ahead of print]
    View PubMed
  242. Abeykoon JP, Gonsalves WI, Oliveira J, Kapoor P. POEMS syndrome: An elusive diagnosis. Am J Hematol. 2017 Nov; 92 (11):1269-1270 Epub 2017 July 29
    View PubMed
  243. Lakshman A, Abeykoon JP, Kumar SK, Rajkumar SV, Dingli D, Buadi FK, Gonsalves WI, Leung N, Dispenzieri A, Kourelis TV, Go RS, Lacy MQ, Hobbs MA, Lin Y, Warsame R, Lust J, Fonder AL, Hwa YL, Hayman SR, Russell SJ, Kyle RA, Gertz MA, Kapoor P. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017 Nov; 92(11):1146-1155. Epub 2017 Sep 08.
    View PubMed
  244. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Rajkumar SV, Dingli D, Leung N, Kyle RA, Kumar SK, Gertz MA. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med. 2017 Nov; 49 (7):545-551 Epub 2017 Mar 27
    View PubMed
  245. Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia. Br J Haematol. 2017 Oct; 179 (1):98-105 Epub 2017 Aug 08
    View PubMed
  246. Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A. Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. Blood. 2017 Sep 28; 130 (13):1578-1584 Epub 2017 Aug 14
    View PubMed
  247. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06
    View PubMed
  248. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
    View PubMed
  249. Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR, Gonsalves W, Warsame R, Kourelis TV, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Dingli D, Leung N, Rajkumar SV, Kyle RA, Kumar SK, Gertz MA. Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol. 2017 Sep; 178 (6):888-895 Epub 2017 July 12
    View PubMed
  250. Tandon N, Sidana S, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Kyle RA, Buadi FK, Dingli D, Hayman SR, Fonder AL, Hobbs MA, Gonsalves WI, Kapoor P, Hwa YL, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Kumar SK. Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. Amyloid. 2017 Sep; 24 (3):183-188 Epub 2017 July 12
    View PubMed
  251. Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017 Sep 1; 7 (9):e600 Epub 2017 Sept 01
    View PubMed
  252. Ghosh T, Gonsalves WI, Jevremovic D, Dispenzieri A, Dingli D, Timm MM, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Kyle RA, Gertz MA, Vincent Rajkumar S, Kumar SK. The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. Am J Hematol. 2017 Sep; 92(9):E507-E512. Epub 2017 Jul 19.
    View PubMed
  253. Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. Haematologica. 2017 Aug; 102 (8):1439-1445 Epub 2017 May 04
    View PubMed
  254. Tandon N, Muchtar E, Sidana S, Dispenzieri A, Lacy MQ, Dingli D, Buadi FK, Hayman SR, Chakraborty R, Hogan WJ, Gonsalves W, Warsame R, Kourelis TV, Leung N, Kapoor P, Kumar SK, Gertz MA. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplant. 2017 Aug; 52 (8):1126-1132 Epub 2017 Apr 10
    View PubMed
  255. Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017 Jul; 31 (7):1562-1569 Epub 2016 Dec 01
    View PubMed
  256. Sidana S, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hwa YL, Leung N, Fonder AL, Hobbs MA, Zeldenrust SR, Russell SJ, Lust JA, Kyle RA, Kumar SK. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol. 2017 Jul; 92 (7):668-673 Epub 2017 May 26
    View PubMed
  257. Ravi P, Kumar S, Gonsalves W, Buadi F, Lacy MQ, Go RS, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma. Blood Cancer J. 2017 Jun 16; 7 (6):e569 Epub 2017 June 16
    View PubMed
  258. Kourelis TV, Kyle RA, Dingli D, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Kapoor P, Go RS, Gonsalves WI, Warsame R, Lust JA, Hayman SR, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, Leung N, Dispenzieri A. Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience. Mayo Clin Proc. 2017 Jun; 92 (6):908-917 Epub 2017 May 05
    View PubMed
  259. Tandon N, Sidana S, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Fonder AL, Hobbs MA, Hayman SR, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. Am J Hematol. 2017 Jun; 92 (6):549-554 Epub 2017 Apr 26
    View PubMed
  260. Muchtar E, Dean DS, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Warsame R, Gonsalves W, Kourelis TV, Go RS, Chakraborty R, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. J Intern Med. 2017 Jun; 281 (6):611-619 Epub 2017 Apr 24
    View PubMed
  261. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Russell S, Kapoor P, Go RS, Kourelis T, Gonsalves W, Zeldenrust SR, Kyle RA, Vincent Rajkumar S, Zemla T, Sloan J, Dispenzieri A. Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. Am J Hematol. 2017 May; 92: (5)435-440.
    View PubMed
  262. Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Stewart AK, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol. 2017 May; 92 (5):467-472 Epub 2017 Mar 22
    View PubMed
  263. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Dispenzieri A. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017 Apr 13; 129 (15):2111-2119 Epub 2017 Jan 26
    View PubMed
  264. Marshall AL, Bartley AC, Ashrani AA, Pruthi RK, Durani U, Gonsalves WI, Kapoor P, Hashmi SK, Siddiqui MA, Go RS. Sex-based disparities in venous thromboembolism outcomes: A National Inpatient Sample (NIS)-based analysis. Vasc Med. 2017 Apr; 22 (2):121-127 Epub 2017 Mar 20
    View PubMed
  265. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11
    View PubMed
  266. Warsame R, Yanamandra U, Kapoor P. POEMS Syndrome: an Enigma. Curr Hematol Malig Rep. 2017 Apr; 12 (2):85-95
    View PubMed
  267. Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Biol Blood Marrow Transplant. 2017 Apr; 23 (4):598-605 Epub 2017 Jan 20
    View PubMed
  268. Chakraborty R, Novak AJ, Ansell SM, Muchtar E, Kapoor P, Hayman SR, Dispenzieri A, Buadi FK, Lacy MQ, King RL, Gertz MA. First report of MYD88(L265P) somatic mutation in IgM-associated light chain amyloidosis. Amyloid 2017 Mar; 24 (sup1):42-43
    View PubMed
  269. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar VS, Gertz MA. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Amyloid 2017 Mar; 24 (sup1):44-45
    View PubMed
  270. Abeykoon JP, Paludo J, Dispenzieri A, Gertz MA, Dingli D, Baudi FK, Gonsalves WI, Kyle RA, Lacy MQ, Hayman SR, Leung N, Kourelis T, Rajkumar SV, Kumar S, Kapoor P. Outcome of very young ( View PubMed
  271. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Amyloid 2017 Mar; 24 (sup1):40-41
    View PubMed
  272. Tandon N, Rajkumar SV, LaPlant B, Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR, Leung N, Go RS, Dingli D, Kapoor P, Lin Y, Hwa YL, Fonder AL, Hobbs MA, Zeldenrust SR, Lust JA, Gonsalves WI, Russell SJ, Kumar SK. Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. Blood Cancer J. 2017 Feb 17; 7 (2):e528
    View PubMed
  273. Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. Leuk Lymphoma. 2017 Feb; 58 (2):308-315 Epub 2016 July 07
    View PubMed
  274. Kapoor P, Rajkumar SV. Multiple myeloma in 2016: Fresh perspectives on treatment and moments of clarity. Nat Rev Clin Oncol. 2017 Feb; 14 (2):73-74 Epub 2017 Jan 10
    View PubMed
  275. Muchtar E, Jevremovic D, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Gonsalves W, Hayman SR, Kapoor P, Leung N, Russell S, Lust JA, Lin Y, Go RS, Chakraborty R, Zeldenrust S, Kumar SK, Kyle RA, Rajkumar SV, Gertz MA. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood. 2017 Jan 5; 129 (1):82-87 Epub 2016 Oct 11
    View PubMed
  276. Hwa YL, Shi Q, Kumar SK, Lacy MQ, Gertz MA, Kapoor P, Buadi FK, Leung N, Dingli D, Go RS, Hayman SR, Gonsalves WI, Russell S, Lust JA, Lin Y, Rajkumar SV, Dispenzieri A. Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. Am J Hematol. 2017 Jan; 92 (1):50-55 Epub 2016 Nov 18
    View PubMed
  277. Muchtar E, Dispenzieri A, Kumar SK, Buadi FK, Lacy MQ, Zeldenrust S, Hayman SR, Leung N, Kourelis TV, Gonsalves W, Chakraborty R, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. Leukemia. 2017 Jan; 31 (1):92-99 Epub 2016 May 23
    View PubMed
  278. Ravindran A, Gonsalves WI, Hashmi SK, Kapoor P, Marshall AL, Siddiqui MA, Go RS. Estimating the annual volume of hematologic cancer cases per hematologist-oncologist in the United States: are we treating rare cancers too rarely? Leuk Lymphoma 2017 Jan; 58 (1):251-252 Epub 2016 June 09
    View PubMed
  279. Chakraborty R, Muchtar E, Kumar S, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant. 2017 Jan; 52 (1):34-40 Epub 2016 Aug 22
    View PubMed
  280. Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, Lacy MQ, Buadi FK, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa L, Kourelis TV, Kyle RA, Gertz MA, Kumar SK. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017 Jan; 31(1):130-135. Epub 2016 Jul 26.
    View PubMed
  281. Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME. Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. JCO Precis Oncol. 2017; 2017 Epub 2017 Aug 01
    View PubMed
  282. Abeykoon JP, Yanamandra U, Kapoor P. New developments in the management of Waldenstrom macroglobulinemia. Cancer Manag Res. 2017; 9:73-83 Epub 2017 Mar 10
    View PubMed
  283. Chakraborty R, Muchtar E, Kumar SK, Jevremovic D, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Blood Cancer J. 2016 Dec 16; 6 (12):e512
    View PubMed
  284. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04
    View PubMed
  285. Paludo J, Painuly U, Kumar S, Gonsalves WI, Rajkumar V, Buadi F, Lacy MQ, Dispenzieri A, Kyle RA, Mauermann ML, McCurdy A, Dingli D, Go RS, Hayman SR, Leung N, Lust JA, Lin Y, Gertz MA, Kapoor P. Myelomatous Involvement of the Central Nervous System. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16 (11):644-654 Epub 2016 Aug 10
    View PubMed
  286. Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016 Nov; 30 (11):2208-2213 Epub 2016 May 23
    View PubMed
  287. Kourelis TV, Nasr SH, Dispenzieri A, Kumar SK, Gertz MA, Fervenza FC, Buadi FK, Lacy MQ, Erickson SB, Cosio FG, Kapoor P, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Gonsalves W, Lorenz EC, Zand L, Kyle RA, Leung N. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016 Nov; 91 (11):1123-1128 Epub 2016 Aug 29
    View PubMed
  288. Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Hwa YL, Gonsalves WI, Zeldenrust SR, Kyle RA, Dispenzieri A. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016 Nov; 91 (11):1129-1134 Epub 2016 Aug 29
    View PubMed
  289. Muchtar E, Dingli D, Kumar S, Buadi FK, Dispenzieri A, Hayman SR, Wolf RC, Gastineau DA, Chakraborty R, Hogan WJ, Leung N, Kapoor P, Lacy MQ, Rajkumar SV, Gertz MA. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. 2016 Nov; 51 (11):1449-1455 Epub 2016 July 04
    View PubMed
  290. Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK, Marshall AL, Ashrani AA, Dispenzieri A, Kyle RA, Rajkumar SV, Go RS. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J 2016 Oct 21; 6 (10):e486
    View PubMed
  291. Muchtar E, Derudas D, Mauermann M, Liewluck T, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Gonsalves W, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clin Proc. 2016 Oct; 91: (10)1354-1361.
    View PubMed
  292. Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, Rajkumar SV, Go RS, Leung N, Kapoor P, Dingli D, Kyle RA, Russell S, Lust JA, Hayman SR, Lin Y, Zeldenrust S, Dispenzieri A. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. Am J Hematol. 2016 Oct; 91 (10):984-8 Epub 2016 July 14
    View PubMed
  293. Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Gertz MA. Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016 Sep; 101 (9):1102-9 Epub 2016 June 16
    View PubMed
  294. Gonsalves WI, Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Go RS, Leung N, Kapoor P, Hayman SR, Lust JA, Russell SJ, Zeldenrust SR, Hwa YL, Kourelis TV, Kyle RA, Kumar SK. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant 2016 Aug; 51 (8):1156-8 Epub 2016 Apr 11
    View PubMed
  295. Leung N, Kumar SK, Glavey SV, Dispenzieri A, Lacy MQ, Buadi FK, Hayman SR, Dingli D, Kapoor P, Zeldenrust SR, Russell SJ, Lust JA, Hogan WJ, Rajkumar SV, Gastineau DA, Kourelis TV, Lin Y, Gonsalves WI, Go RS, Gertz MA. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrol Dial Transplant. 2016 Aug; 31 (8):1284-9 Epub 2015 Nov 30
    View PubMed
  296. Higgins LS, Go RS, Dingli D, Kumar SK, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lust JA, Kapoor P, Leung N, Lin Y, Kourelis TV, Gertz MA, Kyle RA, Gonsalves WI. Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk. 2016 Aug; 16 (8):447-52 Epub 2016 May 05
    View PubMed
  297. Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016 Jul 29; 6 (7):e454 Epub 2016 July 29
    View PubMed
  298. Chakraborty R, Novak AJ, Ansell SM, Muchtar E, Kapoor P, Hayman SR, Dispenzieri A, Buadi FK, Lacy MQ, King RL, Gertz MA. First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood 2016 Jun 9; 127 (23):2936-8 Epub 2016 Mar 31
    View PubMed
  299. Kyle RA, Ansell SM, Kapoor P. Prognostic factors and indications for treatment of Waldenstrom's Macroglobulinemia. Best Pract Res Clin Haematol. 2016 Jun; 29 (2):179-186 Epub 2016 Aug 23
    View PubMed
  300. Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, Go RS, Kapoor P, Lust JA, Hayman SR, Hwa Y, Rajkumar SV, Zeldenrust SR, Russell SJ, Lin Y, Leung N, Kyle RA, Gonsalves WI, Dispenzieri A. Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. Am J Hematol. 2016 Jun; 91 (6):585-9 Epub 2016 Apr 13
    View PubMed
  301. King RL, Gonsalves WI, Ansell SM, Greipp PT, Frederick LA, Viswanatha DS, He R, Kyle RA, Gertz MA, Kapoor P, Morice WG, Howard MT. Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations. Am J Clin Pathol. 2016 Jun; 145 (6):843-51 Epub 2016 June 21
    View PubMed
  302. Gonsalves WI, Timm MM, Rajkumar SV, Morice WG, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res. 2016 May; 44:32-9 Epub 2016 Mar 10
    View PubMed
  303. Mullikin TC, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lin Y, Dingli D, Go RS, Hayman SR, Zeldenrust SR, Russell SJ, Lust JA, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK. Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol. 2016 May; 91 (5):473-5 Epub 2016 Apr 06
    View PubMed
  304. Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, Go RS, Lust JA, Hayman SR, Rajkumar V, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Hwa YL, Gonsalves W, Kyle RA, Dispenzieri A. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016 May; 30 (5):1079-85 Epub 2015 Dec 16
    View PubMed
  305. Nathwani N, Larsen JT, Kapoor P. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Curr Hematol Malig Rep. 2016 Apr; 11 (2):127-36
    View PubMed
  306. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 2016 Mar 11; 6:e401
    View PubMed
  307. Kapoor P, Paludo J, Ansell SM. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Curr Treat Options Oncol. 2016 Mar; 17 (3):16
    View PubMed
  308. Kaufman GP, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, Go RS, Hwa YL, Kyle RA, Rajkumar SV, Kumar SK. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia. 2016 Mar; 30 (3):633-9 Epub 2015 Oct 21
    View PubMed
  309. Kapoor P, Ansell SM, Braggio E. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. Cancer Treat Res. 2016; 169:321-361.
    View PubMed
  310. Cordes S, Gertz MA, Buadi FK, Lin Y, Lacy MQ, Kapoor P, Kumar SK, McCurdy A, Dispenzieri A, Dingli D, Hayman SR, Hogan WJ, Pruthi RK. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagul Fibrinolysis. 2016 Jan; 27: (1)101-8.
    View PubMed
  311. Buadi FK, Gertz MA, Laplant BR, Halvorson A, Lacy MQ, Hayman SR, Dingli D, Kapoor P, Gonsalves WI, Miceli T, Brandes E, Stafford SL, Martenson JA, Hogan WJ and Kumar SK. Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma Blood 2016 .2016;
  312. Majithia N, Vincent Rajkumar S, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, Hayman SR, Dingli D, Kapoor P, Hwa L, Lust JA, Russell SJ, Go RS, Kyle RA, Kumar SK. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am J Hematol. 2015 Nov; 90 (11):981-5 Epub 2015 Oct 06
    View PubMed
  313. Siontis B, Kumar S, Dispenzieri A, Drake MT, Lacy MQ, Buadi F, Dingli D, Kapoor P, Gonsalves W, Gertz MA, Rajkumar SV. Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Blood Cancer J. 2015 Oct 23; 5:e364
    View PubMed
  314. Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hwa YL, Dingli D, Kapoor P, Hayman SR, Lust JA, Kyle RA, Kumar SK. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia. 2015 Oct; 29 (10):2033-8 Epub 2015 May 12
    View PubMed
  315. Chakraborty R, Kapoor P, Ansell SM, Gertz MA. Ibrutinib for the treatment of Waldenstrom macroglobulinemia. Expert Rev Hematol. 2015 Oct; 8 (5):569-79 Epub 2015 July 02
    View PubMed
  316. Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, Kumar SK. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am J Hematol. 2015 Oct; 90: (10)888-91.
    View PubMed
  317. Kapoor P, Paludo J, Vallumsetla N, Greipp PR. Waldenstrom macroglobulinemia: What a hematologist needs to know. Blood Rev. 2015 Sep; 29 (5):301-19 Epub 2015 Mar 24
    View PubMed
  318. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015 Aug 14; 5:e338
    View PubMed
  319. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  320. Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol. 2015 Jun; 90: (6)524-8.
    View PubMed
  321. Mir MA, Kapoor P, Kumar S, Pandey S, Dispenzieri A, Lacy MQ, Dingli D, Hogan W, Buadi F, Hayman S, Gandhi M, Gertz MA. Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 (6):349-357.e2 Epub 2015 Apr 02
    View PubMed
  322. Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Ketterling RP, Lin Y, Russell S, Hwa L, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Dispenzieri A. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J. 2015 May 1; 5:e310 Epub 2015 May 01
    View PubMed
  323. Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, Kurtin PJ, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Lacy MQ, Kapoor P, Kumar S, Kyle RA, Rajkumar SV, Leung N. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc. 2015 May; 90 (5):587-96
    View PubMed
  324. Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Kapoor P, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust S, Kyle RA, Gertz MA, Kumar SK. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2015 Mar 20; 5:e296
    View PubMed
  325. Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Kapoor P, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015 Mar; 90 (3):181-6 Epub 2015 Jan 16
    View PubMed
  326. Vallumsetla N, Paludo J, Kapoor P. Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. Ther Clin Risk Manag. 2015; 11:1663-74 Epub 2015 Nov 06
    View PubMed
  327. Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Kumar S, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N. Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma. 2015; 56 (12):3357-64 Epub 2015 May 12
    View PubMed
  328. Chakraborty R, Ansell SA, Kapoor P, Gertz MA. Phase II clinical trials for Waldenstrom's macroglobulinemia. Expert Opinion on Orphan Drugs. 2015; 3(5):537-47.
  329. Chakraborty R, Kapoor P, Ansell SM, Gertz MA. Emerging therapeutic options for Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. Expert Rev Anticancer Ther. 2015; 15 (10):1143-56 Epub 2015 July 21
    View PubMed
  330. Kourelis TV, Kumar SK, Go RS, Kapoor P, Kyle RA, Buadi FK, Gertz MA, Lacy MQ, Hayman SR, Leung N, Dingli D, Lust JA, Lin Y, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Am J Hematol. 2014 Nov; 89(11):1051-4. Epub 2014 Sep 02.
    View PubMed
  331. Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, Buadi FK, Lacy MQ, Singh PP, Kapoor P, Gertz MA, Kumar SK. Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol. 2014 Nov; 167 (4):500-5 Epub 2014 Aug 12
    View PubMed
  332. Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, Dispenzieri A, Buadi FK, Lacy MQ, Kapoor P, Gertz MA, Kumar SK. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014 Oct; 28(10):2060-5. Epub 2014 Mar 12.
    View PubMed
  333. Paludo J, Kapoor P, Oliveira JL, Garrity JA, Nowakowski GS. Mantle cell lymphoma: a great masquerader. Int J Hematol. 2014 Oct; 100 (4):313-4 Epub 2014 July 30
    View PubMed
  334. Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, Buadi FK, Lacy MQ, Kapoor P, Dingli D, Lust JA, Zeldenrust SR, Hayman SR, Kyle RA, Gertz MA, Kumar SK. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014 Aug 7; 124 (6):907-12 Epub 2014 June 23
    View PubMed
  335. Warsame R, Bang SM, Kumar SK, Gertz MA, Lacy MQ, Buadi F, Dingli D, Hayman SR, Kapoor P, Kyle RA, Leung N, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Rajkumar SV, Dispenzieri A. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. Eur J Haematol. 2014 Jun; 92(6):485-90. Epub 2014 Mar 2
    View PubMed
  336. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014 May; 28 (5):1122-8 Epub 2013 Oct 25
    View PubMed
  337. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014 Apr; 89 (4):484-92 Epub 2014 Feb 26
    View PubMed
  338. Kourelis TV, Kumar SK, Srivastava G, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust SR, Leung N, Kyle RA, Russell SJ, Dingli D, Lust JA, Lin Y, Kapoor P, Go R, Rajkumar SV, Dispenzieri A. Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. Am J Hematol. 2014 Mar; 89 (3):302-5 Epub 2014 Feb 18
    View PubMed
  339. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, Zeldenrust SR, McCurdy A, Greipp PR, Kyle RA, Rajkumar SV, Gertz MA. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol. 2013 Dec 20; 31 (36):4529-35 Epub 2013 Nov 18
    View PubMed
  340. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013 Dec 19; 122 (26):4172-81 Epub 2013 Oct 21
    View PubMed
  341. Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, McCurdy A, Dispenzieri A. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013 Dec 1; 31 (34):4319-24 Epub 2013 Oct 21
    View PubMed
  342. Srivastava G, Rana V, Lacy MQ, Buadi FK, Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell S, McCurdy A, Kapoor P, Kyle R, Rajkumar SV, Kumar S. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia. 2013 Oct; 27 (10):2062-6 Epub 2013 May 07
    View PubMed
  343. Gonsalves WI, Gertz MA, Dispenzieri A, Lacy MQ, Lin Y, Singh PP, Gupta V, Hayman SR, Buadi FK, Dingli D, Kapoor P, McCurdy AR, Kumar SK. Implications of continued response after autologous stem cell transplantation for multiple myeloma. Blood. 2013 Sep 5; 122 (10):1746-9 Epub 2013 July 17
    View PubMed
  344. Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, Kapoor P, Lust JA, Hayman SR, Buadi FK, Rajkumar SV, Zeldenrust SR, Russell SJ, Dingli D, Lin Y, Leung N, Dispenzieri A. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013 Jul 4; 122 (1):68-73 Epub 2013 May 22
    View PubMed
  345. Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2013 May; 88(5):375-8. Epub 2013 Mar 19.
    View PubMed
  346. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ, Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013 Apr; 88 (4):360-76
    View PubMed
  347. Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Semin Hematol. 2012 Jul; 49 (3):228-42
    View PubMed
  348. Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011 Nov; 124(11):1006-15.
    View PubMed
  349. Kapoor P, Rajkumar SV. Update on risk stratification and treatment of newly diagnosed multiple myeloma. Int J Hematol. 2011 Oct; 94 (4):310-320 Epub 2011 Oct 18
    View PubMed
  350. Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011 Apr; 25(4):689-96. Epub 2011 Jan 14.
    View PubMed
  351. Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, Kumar S, Greipp PR. Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience. Mayo Clin Proc. 2010 Oct; 85 (10):905-12 Epub 2010 July 15
    View PubMed
  352. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010 Jun; 85 (6):532-7
    View PubMed
  353. Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med. 2010 Feb; 123(2):111-9.
    View PubMed
  354. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26
    View PubMed
  355. Kapoor P, Snozek CL, Colby C, Larson DR, Katzmann JA, Rajkumar SV, Greipp PR. Clinical impact of discordance in serum albumin measurements on myeloma international staging system. J Clin Oncol 2008 Aug 20; 26 (24):4051-2
    View PubMed
  356. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008 Apr; 141(2):135-48. Epub 2008 Mar 03.
    View PubMed
  357. Chandrashekaran S, Parikh S, Kapoor P, Subbarayan S. Postpartum reversible cerebral vasoconstriction syndrome. Am J Med Sci. 2007 Sep; 334(3):222-4.
    View PubMed
  358. Kapoor P, Singh E, Radhakrishnan P, Mehta P. Splenectomy in plasma cell dyscrasias: a review of the clinical practice. Am J Hematol. 2006 Dec; 81(12):946-54.
    View PubMed
PST-20227092